紫杉醇(白蛋白结合型)联合顺铂治疗晚期复发子宫颈癌的临床效果及安全性分析

Clinical Efficacy and Safety of Paclitaxel(Albumin Binding Type)Combined with Cisplatin in the Treatment of Advanced Recurrent Cervical Cancer

目的:观察紫杉醇(白蛋白结合型)联合顺铂治疗晚期复发子宫颈癌的临床效果,并分析治疗的安全性。方法:选择2020年1月-2021年6月于阳江市人民医院进行晚期子宫颈癌治疗的患者64例。使用随机数字表法将患者分为观察组和对照组,每组32例。对照组使用多西他赛联合顺铂(DP)方案进行治疗,观察组给予注射用紫杉醇(白蛋白结合型)联合顺铂方案进行治疗。比较两组临床疗效、治疗前后肿瘤最大径的变化、肝肾功能变化及不良反应。结果:观察组治疗总有效率为87.50%,明显高于对照组的65.63%(P<0.05)。治疗后,两组肿瘤最大径较治疗前均缩小,且观察组小于对照组,差异均有统计学意义(P<0.05)。治疗后,两组谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL),肾功能指标如血肌酐(Cr)、胱抑素C(CysC)、尿素氮(BUN)均高于治疗前,但观察组上述指标均低于对照组,差异均有统计学意义(P<0.05)。两组骨髓抑制、消化道反应、脱发、肝肾功能损害、外周神经毒性发生程度比较,差异均有统计学意义(P<0.05)。结论:紫杉醇(白蛋白结合型)联合顺铂对晚期复发子宫颈癌具有较好的临床效果,能更好地抑制肿瘤,且安全性较高,对肝肾功能损伤小,副作用更低,具有较好的临床应用前景。

Objective:To observe the clinical efficacy and safety of Paclitaxel(Albumin Binding Type)combined with Cisplatin in the treatment of advanced recurrent cervical cancer.Method:A total of 64 patients with advanced cervical cancer from January 2020 to June 2021 in Yangjiang People’s Hospital were selected.The patients were divided into the observation group and the control group by random number method,32 cases in each group.The control group was treated with Docetaxel combined with Cisplatin(DP),the observation group was treated with Paclitaxel(Albumin Binding Type)combined with Cisplatin regimen.The clinical efficacy,changes in the maximum diameter of tumor and liver and kidney function before and after treatment,and adverse reactions were compared between two groups.Result:The total effective rate of the observation group was 87.50%,which was significantly higher than 65.63%of the control group(P<0.05).After treatment,the maximum diameter of tumor in two groups were smaller than those before treatment,and the observation group was smaller than that in the control group,the differences were statistically significant(P<0.05).After treatment,alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),renal function indicators such as serum creatinine(Cr),cystatin C(CysC),urea nitrogen(BUN)in two groups were higher than those before treatment,but the above indexes in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were significant differences in bone marrow suppression,digestive tract reaction,alopecia,liver and kidney function damage and peripheral neurotoxicity between two groups(P<0.05).Conclusion:Paclitaxel(Albumin Binding Type)combined with Cisplatin has a good clinical effect on advanced recurrent cervical cancer,can better inhibit tumor,and has a high safety,less damage to liver and kidney function,and lower side effects,so it has a good clinical application prospect.